GSK and Empirico Enter License Agreement for Clinical-Stage, First-in-Class Oligonucleotide Candidate to Treat Respiratory Diseases
October 28, 2025
October 28, 2025
LONDON, England, Oct. 28 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases
* siRNA candidate EMP-012 in phase I for treatment of COPD
* EMP-012 targets a distinct inflammatory pathway with enhanced potency and longer dose intervals
* Potential to t . . .
* * *
GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases
* siRNA candidate EMP-012 in phase I for treatment of COPD
* EMP-012 targets a distinct inflammatory pathway with enhanced potency and longer dose intervals
* Potential to t . . .